CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

This trial tests CD70-targeted CAR-T cell therapy for blood cancers — including relapsed or refractory AML (leukemia), B-cell lymphoma (NHL), and multiple myeloma — that have the CD70 marker on cancer cells. CAR-T therapy uses engineered versions of your own immune cells to attack cancer. **You may be eligible if...** - You are 18 or older (no upper age limit for lymphoma; age requirements vary slightly per cancer type) - You have confirmed CD70-positive AML, NHL, or multiple myeloma that has relapsed or not responded to prior treatments - Your heart, liver, and kidney function are within acceptable ranges - Your ECOG performance status is 0–2 - Your life expectancy is at least 3 months **You may NOT be eligible if...** - You have a history of brain injury, epilepsy, or significant stroke - You have serious heart rhythm problems - You are pregnant or breastfeeding - You have severe active infection, active hepatitis B or C, or HIV - You have previously received any CAR-T or genetically modified T-cell therapy Talk to your doctor to see if this trial is right for you.